Welcome
Support Centre
09 February 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Paracetamol (Acetaminophen) In Stroke
ISRCTN ISRCTN74418480
ClinicalTrials.gov identifier
Public title Paracetamol (Acetaminophen) In Stroke
Scientific title
Acronym PAIS
Serial number at source NTR750
Study hypothesis Early antipyretic therapy reduces the risk of death or dependency in patients with acute stroke, even if they are normothermic.
Ethics approval Ethics approval received from the local medical ethics committee
Study design Randomised controlled trial
Countries of recruitment Netherlands
Disease/condition/study domain Acute stroke
Participants - inclusion criteria 1. Clinical diagnosis of acute stroke
2. Possibility to start treatment within 12 hours from onset
3. Brain Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) within 24 hours
4. Age 18 years or older
5. Signed informed consent
Participants - exclusion criteria Abody temperature lower than 36¡ãC or higher than 39¡ãC
A history of liver disease
Alcohol abuse
1. Liver enzymes increased above twice the upper limit of normal
2. Allergy to paracetamol
3. Significant pre-stroke impairment (more than three on the modified Rankin Scale [mRS])
Anticipated start date 01/05/2003
Anticipated end date 01/09/2008
Status of trial Completed
Patient information material
Target number of participants 2500
Interventions Treatment with high dose paracetamol (6 g/day) or placebo will start within 12 hours after onset of symptoms, and continue for three days.
Primary outcome measure(s) Dichotomised mRS (less than or equal to two: good outcome, more than or equal to six: poor outcome) at three months.
Secondary outcome measure(s) 1. Score on the Barthel index after two weeks
2. Body temperature after 24 hours of treatment
3. EuroQol-5D instrument at three months
Sources of funding Netherlands Heart Foundation; known as 'Early antipyretic therapy in acute stroke trial' (ref 2002B148) (The Netherlands)
Trial website
Publications 1. 2003 protocol in Dutch in http://www.ncbi.nlm.nih.gov/pubmed/14574783
2. 2005 protocol in English in http://www.ncbi.nlm.nih.gov/pubmed/16109181
3. 2008 protocol correction in http://www.ncbi.nlm.nih.gov/pubmed/18983661
Contact name Dr  H  den Hertog
  Address Erasmus Medical Center
Department of Neurology, Suite Ee 2240
P.O. Box 2040
  City/town Rotterdam
  Zip/Postcode 3000 CA
  Country Netherlands
  Tel +31 (0)10 4639222
  Email m.denhertog@erasmusmc.nl
Sponsor Erasmus Medical Center (The Netherlands)
  Address Department of Neurology
P.O. Box 2040
  City/town Rotterdam
  Zip/Postcode 3000 CA
  Country Netherlands
Date applied 06/11/2002
Last edited 10/11/2008
Date ISRCTN assigned 06/11/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© ISRCTN


BioMed Central